

UBS China A Opportunity Equity Fund USD P-acc

Performance Review

Performance (basis USD, net of fees)¹

UBS (Lux) Investment SICAV - China A Opportunity (USD) P-acc



Rebased to 100 on the basis of month-end data in % +175 450 400 +150 +125 350 300 +100 250 +75 200 +50 +25 150 100 0 50 -25 -50 0 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Fund performance net of fees (left-hand scale) Fund performance per year in % net of fees (right-hand scale)

..... Index performance (left-hand scale)

Past performance is not a reliable indicator of future results.

Performance in % (net of fees)¹

			-					
in %	2020	2021	2022	2023	2024	Aug.	5 years	Ø p.a. 5
					YTD ²	2024		years
Fund (USD)	37.11	-14.42	-28.90	-13.89	-1.93	0.83	-22.00	-4.85
Benchmark ³	39.70	4.03	-27.23	-11.65	-4.51	-1.92	-0.86	-0.17
The performance	e shown do	pes not t	ake acco	unt of an	ıy commi	ssions, e	entry or e	exit

 These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset

2 YTD: year-to-date (since beginning of the year)

3 Benchmark in currency of share class (without costs)

On the economic front, macro data sent out mixed signals. China's trade surplus came down from its historical high due to a slowdown in exports. Mixed economic activity data and diminished expectations regarding strong policy stimulus put further pressure on the onshore market.

Monthly performance

In August the fund performed positively with 0.8%. Fixed asset investment (FAI) growth slowed to 3.6% year-on-year from January to July due to the continued contraction in real estate investment and further moderation in infrastructure. Meanwhile, retail sales showed a moderate uptick compared to the previous month.

YTD performance

YTD as of the end of August, the fund has delivered a negative performance of 1.9%. The investment environment was choppy, with the market overemphasising the risk factors for Chinese stocks.

Performance contributors

Over the month, healthcare positions, and specifically the Chinese traditional medicine company Yunnan Baiyao, added the most value.

Performance detractors

Positions in communication services detracted. While NetEase's Q2 results slightly missed expectations, with the firm reporting a decline in deferred gaming revenue, we noted that market expectations were high. We believe that the company's rich gaming portfolio should sustain long-term growth in the future.

Internet: www.ubs.com/funds Contact your client advisor Portfolio management representatives Bin Shi Morris Wu Denise Cheung

UBS Fund Infoline: 0800 899 899

For more information

UBS China A Opportunity Equity Fund USD P-acc

Sector exposure (%)

Sectors	Portfolio
Consumer Staples	21.79
Health Care	21.01
Cash	15.00
Financial Services	13.44
Communication Services	12.78
Consumer Discretionary	12.57
Materials	2.10
Real estate	0.90
Industrials	0.41
Energy	0.00
Information Technology	0.00
Utility	0.00

10 largest equity positions (%)¹

	Fund
Kweichow Moutai Co Ltd	10.2
China Merchants Bank Co Ltd	9.4
Yunnan Baiyao Group Co Ltd	9.2
Fuyao Glass Industry Group Co Ltd	5.7
Tencent Holdings Ltd	4.5
NetEase Inc	4.4
Midea Group Co Ltd	3.9
Jiangsu Hengrui Pharmaceuticals Co Ltd	3.9
China Mobile Ltd	3.8
Dong-E-E-Jiao Co Ltd	3.1

1 This is not a recommendation to buy or sell any security

Current investment strategy

As China's growth normalises, investor confidence has taken a hit and valuations remain well below their historical average. Lower valuations can sow the seeds for long-term alpha generation within China. As bottom-up investors, we continue to believe that extensive boots on the ground research is required to identify the best opportunities.

Risks

UBS Opportunity Equity Funds invest in equities and may therefore be subject to high fluctuations in value. As these UBS Funds pursue an active management style, each Fund's performance can deviate substantially from that of it's reference index. All investments are subject to market fluctuations. This Fund has specific risks related to Chinese investments, which can significantly increase given the specific market and market regulation. This Fund may not be appropriate for investors who plan to withdraw their money before the recommended holding period disclosed in the PRIIPs KID, if available for this share class.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Information Document, Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 8 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on www.ubs.com/funds. The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. Before investing in a product please read the latest prospectus and key information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the fund level into consideration (ongoing costs). The entry and exit costs. which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-glossary © UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved